West Palm Beach, FL, Jan. 07, 2022 (GLOBE NEWSWIRE) — USA Equities Corp. (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive value-based healthcare solutions through the use of emerging digital and point of care technologies, recently found additional scientific validation for its digital medicine platform — QHSLab.
A recent article published December 28, 2021, in the Journal of the American Medical Association (JAMA) titled ‘Assessment of an Interactive Digital Health–Based Self-management Program to Reduce Hospitalizations Among Patients With Multiple Chronic Diseases’ reported on the success achieved by physicians utilizing a research system similar with QHSLab. The randomized clinical trial found that “among participants who received the internet chronic disease management intervention, fewer were admitted to the hospital” and “digital health interventions supporting patient self-management and self-monitoring has the potential to augment primary care among patients with multiple chronic diseases and co-morbidities.”
USA Equities Corp offers a digital medicine Software-as-a-Service (SaaS) platform, QHSLab, which includes evidence based digital screening and patient self-management interventions. Through its dynamic algorithms QHSLab identifies the root causes of patients’ chronic disease, not merely the symptoms, and presents its findings to physicians suggesting ways to manage their patients’ diseases. QHSLab currently helps physicians manage allergies, asthma, mental health, and more through a comprehensive platform, not a single disease or health condition only approach like those offered by many other digital health providers.
Physicians are seeking preventive and chronic care management tools for their medical decision making and patient care, including non-face to face interventions and easy to incorporate workflow digital screenings. Today, independent physicians and their practices desire digital health relationships that meet all their needs instead of having to incorporate multiple limited services from numerous digital health companies. Physicians don’t have time to pick and choose among different digital health systems. QHSLab solves this problem especially for the independent primary care provider.
“We see the burden placed on primary care providers to care for patients who present with a myriad of conditions that need ongoing medical management both face to face and non-face to face. Providers are seeking comprehensive and reimbursable tools that provide them with the data and monitoring they need to support their patient caseload while providing first class care,” said USA Equities Corp Chief Executive Officer Troy Grogan.
The recent study published in Jama states that “Implicit in care is successful patient self-management, which includes self-monitoring of symptoms, maintenance of healthy lifestyle behaviors, and management of medications.” QHSLab is a low cost high value service which allows physicians and patients to achieve this objective. QHSLab’s expansion will continue throughout the new year. “We are excited to soon release new reimbursable digital medicine instruments for managing hypertension, asthmatic lung function, chronic pain and obstructive sleep apnea, adding to our existing portfolio and putting even more power in the hands of independent primary care physicians. We’re listening to our physician clients and delivering on what they’re asking for” concluded Grogan.
The Company began the process of changing its name to QHSLab, Inc. by filing a preliminary information statement with the SEC on December 21, 2021. The name change reflects the business, products and services the Company now offers as referenced throughout this press release.
About USA Equities Corp
USA Equities Corp (OTCQB: USAQ) is a medical device company providing digital medicine solutions and point-of-care-diagnostic tests to primary care physicians. Digital medicine allows doctors to assess their patients’ responses quickly and effectively using advanced artificial intelligence algorithms. Digital medicine can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. USAQ also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. USAQ’s products and services are designed to help physicians improve patient monitoring and medical care while also improving the revenues of their practice.
For additional information, visit the Company’s website at www.USAQCorp.com
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor & Media Contact:
Olivia Giamanco
USA Equities Corp
(929) 379-6503
IR@USAQCORP.COM
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…